DOCSLIB.ORG

Ready-To-Use Dasiglucagon Injection As a Fast and Effective Treatment for Severe Hypoglycemia T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ready-To-Use Dasiglucagon Injection As a Fast and Effective Treatment for Severe Hypoglycemia T 477 READY-TO-USE DASIGLUCAGON INJECTION AS A FAST AND EFFECTIVE TREATMENT FOR SEVERE HYPOGLYCEMIA T. Pieber1; R. Tehranchi2; U. Hövelmann3; J. Willard4; L. Plum-Moerschel5; R. Aronson6 1Medical University of Graz, Division of Endocrinology and Diabetology, Graz, Austria, 2Zealand Pharma AS, Clinical & Medical Affairs, Copenhagen, Denmark, 3Profil, Profil, Neuss, Germany, 4ProSciento, Inc., Diabetes, Chula Vista, United States of America, 5Profil, Profil, Mainz, Germany, 6LMC Healthcare, LMC, Toronto, Canada Introduction Primary and All Secondary Endpoints Were Met (continued) • At the present time, glucagon is a first-line treatment option for severe hypoglycemia in patients Dasiglucagon Placebo GlucaGen® Dasiglucagon with insulin-treated diabetes1,2,3 (n = 82) (n = 43) (n = 43) vs Placebo • Overall, patients with type 1 diabetes mellitus (T1DM) do not receive adequate prescription for, Mean increase in plasma glucose from baseline (mg/dL) or education and proper training regarding the use of glucagon kits to treat or prevent severe hypoglycemia1-5 10 minutes 23.9 -0.1 22.0 < 0.001**** • Presently available glucagon kits have required user training and multiple preparation steps that 15 minutes 43.5 5.1 44.1 < 0.001**** are barriers to their prescription and utilization, especially under emergent circumstances1,2 20 minutes 59.7 8.7 58.4 < 0.001**** Dasiglucagon 30 minutes 90.9 19.1 88.5 < 0.001**** • Is a peptide analogue of glucagon, with 7 amino acid substitutions designed to eliminate peptide *Distribution-free. aggregation and fibril formation6 **Log-rank test. • Is physically and chemically stable in aqueous solution, making it a good candidate for use in ****Analysis of Covariance model including treatment group and baseline plasma glucose. 7 single-injection pen applicators Plasma Glucose Concentrations Rapidly and Consistently Increased • Is a specific agonist at the glucagon receptor6 • Dasiglucagon is presented in a ready-to-use formulation With Dasiglucagon • Allows for easy-to-use, simple, auto-injector or pre-filled safety syringe administration • Allows for refrigerated and room temperature storage Mean Plasma Glucose Mean (95% CI) Plasma Glucose, mmol/L 180 Dasiglucagon 0.6 mg 10 Aib A R ® A E E GlucaGen 1.0 mg F K V 160 9 W E S Placebo L T 8 HSQGTFTSDYSKYLD 140 7 120 Substitution 6 Hot-spots 100 5 80 Dasiglucagon Phase 3 Clinical Trial Design 4 Study of dasiglucagon versus placebo for treatment of insulin-induced hypoglycemia in T1DM using 60 3 GlucaGen® as reference* Mean (95% CI) Plasma Glucose, mg/dL 40 0 10 20 30 40 Randomization Dosing Time (min) Dasiglucagon 0.6 mg (n = 82) Median True Time to 20 mg/dL (1.1 mmol/L) Increase in Plasma Glucose Patients ® T1DM; insulin ≥ 1 year; 1-month Plasma Glucose Dasiglucagon Placebo GlucaGen HbA1c < 10%; Placebo (n = 43) safety Recovery* (n = 82) (n = 43) (n = 43) Age: ≥ 18 y to ≤ 70 y follow-up (n = 170) Induction Median (min) 9.0 33.7 10.0 Hypoglycemia GlucaGen® 1.0 mg (n = 43) [95% CI] [8.4, 9.7] [26.1, 36.1] [8.4, 10.6] *Estimated true time to recovery (interpolated between sampling times). 0 4 6 8 10 12 15 17 20 25 30 40 50 60 300 Summary of Adverse Events (AEs) Minutes From Injection (Time points for blood sampling and/or safety assessment) Dasiglucagon 0.6 mg Placebo GlucaGen® 1.0 mg (n = 82) (n = 43) (n = 43) * NCT03378635: A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with T1DM compared to placebo and with reference to GlucaGen®. Number of pts (%) GlucaGen® is a registered trademark of Novo Nordisk A/S. All 66 (80%) 14 (33%) 32 (74%) Primary and Secondary Endpoints Serious 0 0 0 • Primary endpoint Severe 0 0 1 (2%)** – Time to plasma glucose recovery defined as first increase in plasma glucose of ≥ 20 mg/dL Drug related 52 (63%) 3 (7%) 27 (63%) (1.1 mmol/L) from time of SC injection* • Secondary endpoints** Most-frequent ≥ 10% drug related*** – Plasma glucose recovery within 10, 15, 20, and 30 min from time of injection* – Plasma glucose change from baseline at 10, 15, 20, and 30 min from time of injection* Nausea 45 (55%) 1 (2%) 23 (53%) *Without administration of rescue intravenous glucose. Vomiting 19 (23%) 1 (2%) 8 (19%) **Multiplicity adjusted. Headache 8 (10%) 1 (2%) 4 (9%) Baseline Characteristics Were Balanced Between Treatment Groups Leading to discontinuation 0 0 0 ® Dasiglucagon Placebo GlucaGen Total *Treatment-emergent AEs presented. (n = 82) (n = 43) (n = 43) (n = 168) **Severe, and transient AEs of nausea and vomiting. ***All AEs were mild/moderate and transient, except nausea and vomiting reported in one patient in GlucaGen® group. Age (years) Median (range) 37 (18-71) 36 (18-65) 38 (23-66) 38 (18-71) 2 BMI (kg/m ) Median (range) 25 (19-38) 26 (20-34) 26 (19-35) 26 (19-38) Conclusions Gender Female 32 (39%) 16 (37%) 15 (35%) 63 (38%) • Primary and all secondary endpoints were met HbA1c (%) Median (range) 7.4 (5.2-9.7) 7.1 (6.0-9.2) 7.4 (5.4-8.9) 7.3 (5.2-9.7) – Median time to plasma glucose recovery of 10 min with dasiglucagon (placebo 40 min, GlucaGen® 12 min) Diabetes (years) Median (range) 22 (2-56) 18 (3-42) 18 (3-57) 19 (2-57) – 65% of dasiglucagon patients recovered within 10 min (placebo 0%, GlucaGen® 49%) BMI: Body Mass Index. – 99% of dasiglucagon patients recovered within 15 min (placebo 2%, GlucaGen® 95%) • Similar rates of nausea and vomiting were reported for both dasiglucagon and GlucaGen® Primary and All Secondary Endpoints Were Met • Dasiglucagon has the potential to be a fast and effective treatment for severe hypoglycemia Dasiglucagon Placebo GlucaGen® Dasiglucagon (n = 82) (n = 43) (n = 43) vs Placebo References 1. Harris G, Diment A, Sulway M, Wilkinson M. Glucagon administration–underevaluated and undertaught. Pract Diabetes Int. Time to plasma glucose recovery (minutes) 2001;18(1):22-25. 2. Kedia N. Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. Diabetes Metab Syndr Median (95% CI)* 10 (10, 10) 40 (30, 40) 12 (10, 12) P < 0.001** Obes. 2011;4:337-346. 3. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S66-S76. Plasma glucose increase of 20 mg/dL (1.1 mmol/L) 4. Mitchell BD, He X, Sturdy IM, Cagle AP, Settles JA. Glucagon Prescription Patterns in Patients With Either Type 1 or 2 Diabetes With Newly Prescribed Insulin. Endocr Pract. 2016;22:123-135. 10 minutes 65% 0% 49% < 0.001*** 5. Haymond MW, Liu J, Bispham J, Hickey A, McAuliffe-Fogarty AH. Use of Glucagon in Patients With Type 1 Diabetes. Clin Diabetes. 2019;37:162-166. 15 minutes 99% 2% 95% < 0.001*** 6. Hövelmann U, Bysted BV, Mouritzen U, et al. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care. 2018;41:531-537. 7. Hövelmann U, Olsen MB, Mouritzen U, Lamers D, Kronshage B, Heise T. Low doses of dasiglucagon consistently increase plasma 20 minutes 99% 14% 98% < 0.001*** glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus. Diabetes Obes Metab. 2019;21:601-610. 30 minutes 100% 47% 100% < 0.001*** Disclosures and Acknowledgements *Distribution-free. Zealand Pharma • Is the developer of dasiglucagon, and the sponsor of this clinical trial **Log-rank test. ***Fisher’s Exact test. Medical writing services provided by José L. Walewski, PhD of rareLife solutions, S. Norwalk, CT, USA were funded by Zealand Pharma A/S of Søborg, Denmark. Presented at the ATTD 2020 Congress, Madrid, Spain February 19 – 22, 2020.
Load more

Recommended publications
  • LANTUS® (Insulin Glargine [Rdna Origin] Injection)
    Rev. March 2007 Rx Only LANTUS® (insulin glargine [rDNA origin] injection) LANTUS® must NOT be diluted or mixed with any other insulin or solution. DESCRIPTION LANTUS® (insulin glargine [rDNA origin] injection) is a sterile solution of insulin glargine for use as an injection. Insulin glargine is a recombinant human insulin analog that is a long-acting (up to 24-hour duration of action), parenteral blood-glucose-lowering agent. (See CLINICAL PHARMACOLOGY). LANTUS is produced by recombinant DNA technology utilizing a non- pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, it is 21A- B B Gly-30 a-L-Arg-30 b-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063. It has the following structural formula: LANTUS consists of insulin glargine dissolved in a clear aqueous fluid. Each milliliter of LANTUS (insulin glargine injection) contains 100 IU (3.6378 mg) insulin glargine. Inactive ingredients for the 10 mL vial are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 mcg polysorbate 20, and water for injection. Inactive ingredients for the 3 mL cartridge are 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for injection. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. LANTUS has a pH of approximately 4. CLINICAL PHARMACOLOGY Mechanism of Action: The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism.
    [Show full text]
  • Insulin Aspart Sanofi, If It Is Coloured Or It Has Solid Pieces in It
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Insulin aspart Sanofi 100 units/ml solution for injection in vial Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution contains 100 units insulin aspart* (equivalent to 3.5 mg). Insulin aspart Sanofi 100 units/ml solution for injection in vial Each vial contains 10 ml equivalent to 1,000 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Each cartridge contains 3 ml equivalent to 300 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen Each pre-filled pen contains 3 ml equivalent to 300 units insulin aspart. Each pre-filled pen delivers 1-80 units in steps of 1 unit. *produced in Escherichia coli by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless, aqueous solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. 4.2 Posology and method of administration Posology The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
    [Show full text]
  • Performance of the Insulin-Only Ilet Bionic Pancreas and The
    e118 Diabetes Care Volume 44, June 2021 Performance of the Insulin-Only Luz E. Castellanos,1 Courtney A. Balliro,1 Jordan S. Sherwood,1 Rabab Jafri,1 iLet Bionic Pancreas and the Mallory A. Hillard,1 Evelyn Greaux,1 Rajendranath Selagamsetty,2 Hui Zheng,3 Bihormonal iLet Using Firas H. El-Khatib,2 Edward R. Damiano,2,4 and Dasiglucagon in Adults With Type Steven J. Russell1 1 Diabetes in a Home-Use Setting Diabetes Care 2021;44:e118–e120 | https://doi.org/10.2337/dc20-1086 Reductions in blood glucose levels in with insulin lispro (Eli Lilly) or aspart (Table 1). The mean CGM glucose and people with diabetes are often achieved (Novo Nordisk), the bihormonal iLet for time in range (70–180 mg/dL) were 149 at the expense of increased hypoglyce- 7dayswithdasiglucagon(4mg/mL) ±13mg/dLand72±8%,respectively,in mia. A novel approach is to automati- and insulin lispro or aspart, or both, us- the insulin-only period, and 139 ± 11 cally deliver microdose glucagon when ing the same glucose target (110 mg/ mg/dL and 79 ± 9%, respectively, in the automation of insulin delivery alone is dL), in random order. There were no re- bihormonal period. The mean daily car- not sufficient to prevent hypoglycemia. strictions on diet or exercise. The prima- bohydrates consumed to prevent or The approach requires a bihormonal de- ry outcomes were prespecified iLet treat hypoglycemia were 16 ± 13 g and vice and a stable form of glucagon or operational thresholds. The key second- 18 ± 21 g in the insulin-only and bihor- glucagon analog.
    [Show full text]
  • Glucose Regulation in Diabetes
    Glucose Regulation in Diabetes Samantha Lozada Advised by Charles S. Peskin and Thomas Fai Glucose 1 Abstract Complicated and extensive models of glucose regulation, involving several variables, have been developed over the years. Our research specifically focuses on the feedback loop between insulin and glucagon. Although our model is simpler than a model including state variables such as non-esterified fatty acids concentration in the blood plasma, β-cell mass, TAG content of lipocytes, and/or leptin concentrations in the blood plasma, we are still able to simulate most of the key effects of diabetes and other health problems on glucose regulation; such as, hyperglycemia, hyperinsulinism, and insulin shock (hypoglycemia). We are even able to simulate eating a bowl of vanilla ice cream! 2 Introduction For most of our qualitative and quantitative experimentations we worked with MATLAB, a computer programming language and data visualization software, which offers a rich set of tools for solving problems in engineering, scientific, computing, and mathematical disciplines, such as a graphical user interface. Our model is a refinement of a realistic model developed by Cobelli et al. (1982). Despite the fact that the paper is nearly 28 years old, the experimental data of diagnostic tests used by medical professionals, such as the Intravenous Glucose Tolerance Test (IVGTT), correlates with our simulated graphs. From a Biological Perspective Regulation in a Healthy System In order for us to model any biological system, we need to first understand exactly what is happening within a human body. We need to ask what causes this effect and why. To answer these questions we need to identify the key organs and hormones, and then see how they interact within our bodies.
    [Show full text]
  • Diabetes Is a Disease in Which the Body's Ability to Produce Or Respond
    Early Signs and Symptoms of diabetes: Early symptoms of diabetes, especially type 2 diabetes, can be subtle or seemingly harmless. Over time, however, you may Diabetes is a disease in which the develop diabetes complications, even if you body’s ability to produce or respond to haven't had diabetes symptoms. In the the hormone insulin is impaired, United States alone, more than 8 million resulting in abnormal metabolism of people have undiagnosed diabetes, Treatments: carbohydrates and elevated levels of according to the American Diabetes Association. Understanding possible glucose (sugar) in the blood. • Insulin therapy diabetes symptoms can lead to early • Oral medications diagnosis and treatment and a lifetime of Diabetes can be broken down into • better health. If you're experiencing any of Diet changes two types, Type 1 and Type 2. Type 1 • Exercise diabetes involves the the following diabetes signs and symptoms, see your doctor. body attacking itself by The medications you take vary by mistake, this then the type of diabetes and how well the causes the body to stop making insulin. With medicine controls you blood glucose levels. Type 2 diabetes the Type 1 diabetics must have insulin. Type 2 body does not respond may or may not include insulin and may just like it should to the be controlled with diet and exercise alone. insulin the pancreas is If you notice any of these changes notify making. Your body tells the pancreas that it needs to make more insulin since the your health care provider. The earlier • insulin that is already there is not working.
    [Show full text]
  • OZEMPIC (Semaglutide) Injection, for Subcutaneous Use Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙CONTRAINDICATIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ These highlights do not include all the information needed to use Personal or family history of medullary thyroid carcinoma or in patients OZEMPIC® safely and effectively. See full prescribing information with Multiple Endocrine Neoplasia syndrome type 2 (4). for OZEMPIC. Known hypersensitivity to OZEMPIC or any of the product components (4). OZEMPIC (semaglutide) injection, for subcutaneous use Initial U.S. Approval: 2017 ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙WARNINGS AND PRECAUTIONS∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ Pancreatitis: Has been reported in clinical trials. Discontinue promptly if WARNING: RISK OF THYROID C-CELL TUMORS pancreatitis is suspected. Do not restart if pancreatitis is confirmed (5.2). See full prescribing information for complete boxed warning. Diabetic Retinopathy Complications: Has been reported in a clinical trial. Patients with a history of diabetic retinopathy should be monitored (5.3). In rodents, semaglutide causes thyroid C-cell tumors. It is Never share an OZEMPIC pen between patients, even if the needle is unknown whether OZEMPIC causes thyroid C-cell tumors, changed (5.4). including medullary thyroid carcinoma (MTC), in humans as Hypoglycemia: When OZEMPIC is used with an insulin secretagogue or the human relevance of semaglutide-induced rodent thyroid C- insulin, consider lowering the dose of the secretagogue or insulin to reduce cell tumors has not been determined (5.1, 13.1). the risk of hypoglycemia (5.5). OZEMPIC is contraindicated in patients with a personal or Acute Kidney Injury: Monitor renal function in patients with renal family history of MTC or in patients with Multiple Endocrine impairment reporting severe adverse gastrointestinal reactions (5.6). Neoplasia syndrome type 2 (MEN 2).
    [Show full text]
  • Prediabetes: What Is It and What Can I Do?
    Prediabetes: What Is It and What Can I Do? What is prediabetes? Weight loss can delay or prevent diabetes. Prediabetes is a condition that comes before Reaching a healthy weight can help you a lot. diabetes. It means your blood glucose levels are If you’re overweight, any weight loss, even higher than normal but aren’t high enough to be 7 percent of your weight (for example, losing called diabetes. about 15 pounds if you weigh 200), may lower your risk for diabetes. There are no clear symptoms of prediabetes. You can have it and not know it. If I have prediabetes, what does it mean? It means you might get type 2 diabetes soon or down the road. You are also more likely to get heart disease or have a stroke. The good news is that you can take steps to delay or prevent type 2 diabetes. How can I delay or prevent type 2 diabetes? You may be able to delay or prevent type 2 diabetes with: Daily physical activity, such as walking. Weight loss, if needed. Losing even a few pounds will help. Medication, if your doctor prescribes it. If you have prediabetes, these steps may bring your blood glucose to a normal range. But you are still at a higher risk for type 2 diabetes. Regular physical activity can delay or prevent diabetes. Being active is one of the best ways to delay or prevent type 2 diabetes. It can also lower your weight and blood pressure, and improve cholesterol levels. Ask your health care team about activities that are safe for you.
    [Show full text]
  • Religious Fasting, Ramadan and Hypoglycemia in People with Diabetes
    VOLUME 7 > ISSUE 01 > JUNE 30 2014 SPOTLIGHT ARTICLE Diabetic Hypoglycemia June 2014, Volume 7, Issue 1: page 15-19 Religious fasting, Ramadan and hypoglycemia in people with diabetes Alia Gilani1, Melanie Davies2, Kamlesh Khunti2 1 NHS Glasgow, United Kingdom 2 Leicester Diabetes Centre, Leicester General Hospital, Leicester, United Kingdom Abstract Most Muslims with diabetes will take part in Ramadan even though they may be exempt from doing so. In some countries a religious fast can last between 10 and 21 hours. The main risk of fasting to people with diabetes is hypoglycemia. People with diabetes who fast may have to alter the dose of their medications or modify their therapeutic regimen to avoid hypoglycemia, which can have adverse effects on glycemic control. Therapies which pose a high risk of hypoglycemia when used during fasting are sulfonylureas and insulin therapy. Metformin, incretin therapies and the newer sodium glucose co-transporter 2 inhibitor class have a low risk of hypoglycemia. The practice of fasting during Ramadan is advocated for all healthy individuals. If deemed detrimental to health then a person can be considered exempt from fasting; this includes frail and elderly people, pregnant and breast feeding women, children and people with multi-morbidities. Keywords: diabetes, hypoglycemia, Ramadan, religious fasting Introduction the Islamic calendar, the risks associated with prolonged fasting and how it should be managed. Living in a diverse society, it is important that healthcare professionals are kept informed about cultural and religious Fasting during Ramadan practices, which can affect the control of diabetes. The practice of fasting by Muslims has implications for Muslim What does fasting entail? people with diabetes, in particular an increased risk of Ramadan in Arabic is translated as “sawm”, literally hypoglycemia during the period of Ramadan and at other meaning “abstention from”.
    [Show full text]
  • Study Protocol
    CLINICAL TRIAL REPORT ZP4207-16136 (ZEA-DNK-01711) 16.1 TRIAL INFORMATION 16.1.1 PROTOCOL AND PROTOCOL AMENDMENTS This appendix includes Document Date, Version Clinical Trial Protocol 18 January 2017, Version 1 Amendment 01 08 May 2017 Clinical Trial Protocol 08 May 2017, Version 2 Amendment 02 21 August 2017 Clinical Trial Protocol 21 August 2017, Version 3 Section 16.1.1: Protocol and Protocol Amendments Clinical Trial Protocol, final version 1 ZP4207-16136 (ZEA-DNK-01711) Clinical Trial Protocol A phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon Compared to GlucaGen® Administered Subcutaneously in Patients with Type 1 Diabetes Mellitus (T1DM) Sponsor code: ZP4207-16136 SynteractHCR: ZEA-DNK-01711 EudraCT number: 2017-000062-30 Coordinating investigator: Linda Morrow, MD Prosciento 855 Third Avenue 91911 Chula Vista CA, USA Sponsor: Zealand Pharma A/S Smedeland 36 2600 Glostrup, Copenhagen Denmark Version: final version 1 Date: 18 January 2017 GCP statement This trial will be performed in compliance with Good Clinical Practice (GCP), the Declaration of Helsinki (with amendments) and local legal and regulatory requirements. 18 Jan 2017 CONFIDENTIAL Page 1/48 Clinical Trial Protocol, final version 1 ZP4207-16136 (ZEA-DNK-01711) Title: A phase 3, randomized, double-blind, parallel group safety trial to evaluate the immunogenicity of dasiglucagon compared to GlucaGen® administered subcutaneously in patients with type 1 diabetes mellitus (T1DM) I agree to conduct this trial according to the Trial Protocol. I agree that the trial will be carried out in accordance with Good Clinical Practice (GCP), with the Declaration of Helsinki (with amendments) and with the laws and regulations of the countries in which the trial takes place.
    [Show full text]
  • Type 2 Diabetes Adult Outpatient Insulin Guidelines
    Diabetes Coalition of California TYPE 2 DIABETES ADULT OUTPATIENT INSULIN GUIDELINES GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes 6,7,8 medications. (Consider insulin as initial therapy if A1C very high, such as > 10.0%) 6,7,8 Start with BASAL INSULIN for most patients 1,6 Consider the following goals ADA A1C Goals: A1C < 7.0 for most patients A1C > 7.0 (consider 7.0-7.9) for higher risk patients 1. History of severe hypoglycemia 2. Multiple co-morbid conditions 3. Long standing diabetes 4. Limited life expectancy 5. Advanced complications or 6. Difficult to control despite use of insulin ADA Glucose Goals*: Fasting and premeal glucose < 130 Peak post-meal glucose (1-2 hours after meal) < 180 Difference between premeal and post-meal glucose < 50 *for higher risk patients individualize glucose goals in order to avoid hypoglycemia BASAL INSULIN Intermediate-acting: NPH Note: NPH insulin has elevated risk of hypoglycemia so use with extra caution6,8,15,17,25,32 Long-acting: Glargine (Lantus®) Detemir (Levemir®) 6,7,8 Basal insulin is best starting insulin choice for most patients (if fasting glucose above goal). 6,7 8 Start one of the intermediate-acting or long-acting insulins listed above. Start insulin at night. When starting basal insulin: Continue secretagogues. Continue metformin. 7,8,20,29 Note: if NPH causes nocturnal hypoglycemia, consider switching NPH to long-acting insulin. 17,25,32 STARTING DOSE: Start dose: 10 units6,7,8,11,12,13,14,16,19,20,21,22,25 Consider using a lower starting dose (such as 0.1 units/kg/day32) especially if 17,19 patient is thin or has a fasting glucose only minimally above goal.
    [Show full text]
  • Insulin Aspart (Nvolog): Important Patient Information
    What is most important to remember? If you have questions: Strong Internal Medicine • Insulin aspart (Novolog®) is used to lower blood sugar. It is Ask your doctor, nurse or pharmacist for important to use this medicine as more information about insulin aspart directed by your doctor (Novolog®) • Do not start any new medicines, over-the-counter drugs or herbal remedies without talking to your doctor • Tell all doctors, dentists and pharmacists that you are using insulin aspart (Novolog®) • insulin aspart (Novolog®) can cause low blood sugar. Always Strong Internal Medicine keep a source of sugar handy for 601 Elmwood Avenue times when your blood sugar gets Ambulatory Care Facility, 5th Floor too low Rochester, NY 14642 Phone: (585) 275 -7424 Insulin Aspart • Do not use your insulin if it (Novolog®): Visit our website at: becomes cloudy or has particles www.urmc.rochester.edu/medicine/ - Important Patient Information in it general-medicine/patientcare/ • Throw away all opened insulin after 28 days, even if it is not used up What does insulin aspart (Novolog®) do? Are there any interactions with other drugs that I need What are some things that I need to be aware of when to worry about? taking insulin aspart (Novolog®)? • It is used to lower blood sugar in patient with high blood sugar (diabetes) • There are many drug interactions that may increase • Tell your doctor or pharmacist if you have an allergy to How should insulin aspart (Novolog®) be used? your risk of side effects insulin, or any other drugs, foods, or substances • Use this
    [Show full text]
  • Low Blood Glucose (Hypoglycemia)
    Low Blood Glucose (Hypoglycemia) Hypoglycemia, also known as low blood Hunger, nausea glucose (blood sugar), is when your blood Color draining from skin (pallor) glucose levels have fallen low enough that you need to take action to bring them back Feeling sleepy to your target range. This is usually when your blood glucose is less than 70 mg/dL. However, Feeling weak, having no energy talk to your doctor about your own blood Blurred/impaired vision glucose targets, and what level is too low for you. Tingling or numbness in lips, tongue, cheeks Headaches When can it happen? Coordination problems, clumsiness Low blood glucose can happen if you’ve skipped a meal or snack, eaten less than usual, or been Nightmares or crying out in sleep more physically active than usual. If you don’t Seizures take steps to bring glucose levels back to normal, you could even pass out. What should you do? What are the symptoms? The 15-15 rule—have 15 grams of carbohydrate to raise your blood glucose and check it after Each person’s reaction to low blood glucose is 15 minutes. If it’s still below 70 mg/dL, have different. It’s important that you learn your own another serving. signs and symptoms when your blood glucose is low. Repeat these steps until your blood glucose is at least 70 mg/dL. Once your blood glucose is back Signs and to normal, eat a meal or snack to make sure it symptoms of doesn’t lower again. low blood glucose include: This may be: Feeling shaky Glucose tablets (see instructions) Being nervous Gel tube (see instructions) or anxious 4 ounces (1/2 cups) of juice or regular soda Sweating, chills, (not diet) clamminess 1 tablespoon of sugar, honey, or corn syrup Mood swings, irritability, impatience 8 ounces of nonfat or 1% milk Confusion Hard candies, jellybeans, or gumdrops—see Fast heartbeat food label for how many to consume Feeling light-headed or dizzy Continued » Visit diabetes.org or call 800-DIABETES (800-342-2383) for more resources from the American Diabetes Association.
    [Show full text]